Researchers combined a new and established biomarker to detect nearly 70 percent of pancreatic cancers with a less than 5 percent false-positive rate.
The test is designed to analyze a panel of 112 genes to help in the diagnosis of thyroid nodules with indeterminate fine-needle aspiration cytology.
The system is designed to identify various cell types and features in whole-slide images of prostate core needle biopsies.
Clinicians were surprised by a recent NEJM study that found that using procalcitonin assays did not reduce the use of antibiotics.
UPitt researchers found that using an FDA-cleared procalcitonin assay did not significantly change the use of antibiotics for patients suspected of having lower respiratory tract infections.
The test was developed by the University of Pittsburgh Medical Center and is marketed in partnership with Sonic Healthcare.
The seven-gene NGS-based test is available for patients who are found to have pancreatic cysts, and can help physicians decide whether to remove them.
A research collaboration involving several universities has yielded a technique that they said isolates exosomes from biological samples more effectively than incumbent methods.
The blood-based test is based on three serum biomarkers —matrix metallopeptidase-9, neuron-specific enolase, and vascular cellular adhesion molecule-1.